Hugh S. Weily, M.D.; Edward Genton, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
Although it is a frequently used antiarrhythmic agent, the routes and mechanisms of procainamide excretion and the effect of urine pH, urine flow rate, and disease states on its renal clearance, plasma half-time, and 6-hr renal excretion have not been defined. Procainamide was administered intravenously to 20 mongrel dogs and 15 humans in a 500-mg bolus or by constant infusion. The 6-hr excretion averaged 65% in normal humans and dogs. Patients with primary renal disease and renal impairment secondary to cardiac failure or hepatic disease had prolonged T½ (5.85 ± 0.39 hr) and decreased renal excretion (40.8 ± 1.8%) compared
Weily HS, Genton E. Clinical Pharmacology of Procainamide.. Ann Intern Med. ;74:823. doi: 10.7326/0003-4819-74-5-823_1
Download citation file:
Published: Ann Intern Med. 1971;74(5):823.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use